Cargando…

Immunotherapy: TIMING OF DONOR SELECTION ON CD45RA-MEMORY T CELLS AS ADOPTIVE CELL THERAPY FOR COVID-19

Detalles Bibliográficos
Autores principales:	Al-Akioui, K., Díaz-Almirón, M., Vicario, J.L., Balas, A., Hidalgo, M. Moreno, Soria, B., Perez-Martinez, A., Ferreras, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Society for Cell & Gene Therapy. Published by Elsevier Inc. 2022
Materias:	POSTER ABSTRACTS: Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035760/ http://dx.doi.org/10.1016/S1465-3249(22)00307-3

Ejemplares similares

Cellular and Humoral Responses from Sars-Cov-2 Specific CD45RA- Memory T Cells from Convalescent and Naive Donors. Clinical Application As an Adoptive Cell Therapy for COVID-19
por: Sanz, Karima AL-Akioui, et al.
Publicado: (2022)

Donor selection for adoptive cell therapy with CD45RA(−) memory T cells for patients with coronavirus disease 2019, and dexamethasone and interleukin-15 effects on the phenotype, proliferation and interferon gamma release
por: Al-Akioui-Sanz, Karima, et al.
Publicado: (2023)

A Phase I/II Dose-Escalation Multi-Center Study to Evaluate the Safety of Infusion of Natural Killer Cells or Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia: (RELEASE NCT04578210)
por: Pérez-Martínez, Antonio, et al.
Publicado: (2021)

Adoptive T Cell Immunotherapy for Cancer
por: Perica, Karlo, et al.
Publicado: (2015)

Immunotherapy: EVALUATION OF MEMORY T CELLS AS ADOPTIVE THERAPY IN CORONAVIRUS PNEUMONIA AND/OR LYMPHOPENIA: A PHASE II CLINICAL TRIAL (RELEASE NCT04578210)
por: Ferreras, C., et al.
Publicado: (2023)

Familial CD45RA(–) T cells to treat severe refractory infections in immunocompromised patients
por: Al-Akioui Sanz, Karima, et al.
Publicado: (2023)

Immunotherapy: ADOPTIVE T CELL IMMUNOTHERAPY FOR SARS-COV-2
por: Henden, A., et al.
Publicado: (2023)

SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy
por: Ferreras, C., et al.
Publicado: (2021)

Identifying SARS‐CoV‐2 ‘memory’ NK cells from COVID‐19 convalescent donors for adoptive cell therapy
por: Herrera, Lara, et al.
Publicado: (2021)

IMMU-16. Next-generation CAR T-cells targeting IL13RA2 and secreting IL-15 achieve durable tumour clearance in pre-clinical model of diffuse midline glioma
por: Hotblack, Alastair, et al.
Publicado: (2022)

IMMU-15. PROTEOGENOMIC DISCOVERY OF NOVEL TUMOR PEPTIDES AS NEOANTIGENS FOR PERSONALIZED T CELL IMMUNOTHERAPY IN MEDULLOBLASTOMA
por: Rivero-Hinojosa, Samuel, et al.
Publicado: (2020)

A Phase II Randomized Multi-Center Study to Evaluate the Safety and Efficacy of Infusion of Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia (RELEASE NCT04578210)
por: Perez, Antonio, et al.
Publicado: (2022)

A Phase II Randomized Multi-Center Study to Evaluate the Safety and Efficacy of Infusion of Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia (RELEASE NCT04578210)
por: Perez-Martinez, Antonio, et al.
Publicado: (2023)

IMMU-06. T-CELL IMMUNOTHERAPY FOR PEDIATRIC BRAIN TUMORS: DIVERSITY IN CELL SURFACE ANTIGEN AND HLA EXPRESSION NECESSITATES A MULTI-PRONGED APPROACH
por: Houke, Haley, et al.
Publicado: (2020)

IMMU-16. INTRA-TUMOURAL IL-12 DELIVERY ENABLES CAR T-CELL IMMUNOTHERAPY FOR HIGH-GRADE GLIOMA
por: Agliardi, Giulia, et al.
Publicado: (2020)

IMMU-12. PHASE I/II TRIAL OF IMMUNOTHERAPY WITH FUSIONS OF DENDRITIC CELLS AND TUMOR CELLS FOR RELAPSED OR REFRACTORY BRAIN TUMORS IN CHILDREN AND YOUNG ADULTS
por: Yamaoka, Masayoshi, et al.
Publicado: (2020)

IMMU-22. PHASE IB IMMUNOTHERAPY CLINICAL TRIAL WITH THE USE OF AUTOLOGOUS DENDRITIC CELLS PULSED WITH AN ALLOGENIC TUMORAL CELL LINES LYSATE IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Madrid, Andres Morales La, et al.
Publicado: (2020)

IMMU-02. Targeted innovative antibody fragment-based immunotherapy for medulloblastoma
por: Niesen, Judith, et al.
Publicado: (2022)

IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2020)

Developing in vitro expanded CD45RA(+) regulatory T cells as an adoptive cell therapy for Crohn's disease
por: Canavan, James B, et al.
Publicado: (2016)

IMMU-19. HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-kB PATHWAYS
por: Marquardt, Viktoria, et al.
Publicado: (2020)

Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE)
por: Pérez-Martínez, A., et al.
Publicado: (2021)

The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma
por: Dibajnia, Pooya, et al.
Publicado: (2023)

Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
por: Gebrael, Georges, et al.
Publicado: (2023)

Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy
por: Sharma, Sandhya, et al.
Publicado: (2023)

Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy
por: Shi, Lin, et al.
Publicado: (2023)

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
por: Reschke, Robin, et al.
Publicado: (2021)

Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells
por: Sun, Roger, et al.
Publicado: (2020)

Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy
por: Hasan, Aisha N., et al.
Publicado: (2022)

P063: Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial
por: Bröckelmann, Paul J., et al.
Publicado: (2022)

A phase I/II dose-escalation single center study to evaluate the safety of infusion of memory t cells as adoptive therapy in coronavirus pneumonia and /or lymphopenia (release)
por: Perez-Martinez, A., et al.
Publicado: (2021)

Bibliometric analysis on the progress of immunotherapy in renal cell carcinoma from 2003-2022
por: Zhu, Haiyan, et al.
Publicado: (2023)

Transcriptional Analysis of Total CD8(+) T Cells and CD8(+)CD45RA(-) Memory T Cells From Young and Old Healthy Blood Donors
por: Toma, Georgiana, et al.
Publicado: (2022)

Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study
por: Rossi, Ernesto, et al.
Publicado: (2023)

Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors
por: Tamaki, Masaharu, et al.
Publicado: (2022)

CD71(+) erythroid cells suppress T-cell effector functions and predict immunotherapy outcomes in patients with virus-associated solid tumors
por: Bozorgmehr, Najmeh, et al.
Publicado: (2023)

COVID-19 Vaccination and Anti-CD19 CAR T Cell-Induced B Cell Aplasia
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Discovery and validation of surface N-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets
por: Oldham, Robyn A A, et al.
Publicado: (2020)

Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy
por: Hwang, Michael, et al.
Publicado: (2022)

Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity
por: Sorin, Mark, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d60jao23d7eh1k1mcpgriasuds